Meeting Banner
Abstract #1374

IDH-1 Mutation and Non-Enhancing Component of Glioblastoma

Daniel M Fountain1, Timothy J Larkin2, Natalie R Boonzaier2, Jiun-Lin Yan2, and Stephen J Price2

1The Brain Tumour Imaging Laboratory, Division of Neurosurgery, University of Cambridge, Cambridge, United Kingdom, 2Division of Neurosurgery and Wolfson Brain Imaging Centre, The Brain Tumour Imaging Laboratory, Cambridge, United Kingdom

IDH-1 mutated glioblastoma is associated with improved survival, and greater sensitivity to further resection of non-enhancing disease than IDH-1 wild-type. We used structural, diffusion tensor, perfusion and spectroscopic imaging data in a mixed model across the peritumoral region in 54 patients. Applying a mixed model methodology across three levels of data resolution, we demonstrated that IDH-1 mutated tumors demonstrated raised choline and lowered glutamate and glutamine compared to IDH-1 wild-type. The findings provided an AUC of 0.943 when combined with age. We hypothesised this results in greater sensitivity to treatment and reduced excitotoxicity, thus explaining their relatively superior prognosis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here